Compile Data Set for Download or QSAR
Report error Found 152 of ic50 data for complexid = 218
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476704( (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-di...)
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM546731((3-(5-chloro-2-((3-cyclopropyl-5-(((3R, 5S)-3,5-di...)
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: 0.5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538658(NCGC 00249373 | US11254667, Compound I-17 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50: 0.880nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622506(US20230312583, Compound I-2)
Affinity DataIC50: 1.09nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622516(US20230312583, Compound I-12)
Affinity DataIC50: 1.26nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622511(US20230312583, Compound I-7)
Affinity DataIC50: 1.34nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622523(US20230312583, Compound V-1)
Affinity DataIC50: 1.44nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476695(5-chloro-4-(6-chloro-1H-indole-3-yl)-N-(3-cyclopro...)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476695(5-chloro-4-(6-chloro-1H-indole-3-yl)-N-(3-cyclopro...)
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622524(US20230312583, Compound VI-1)
Affinity DataIC50: 1.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM681989(US12018014, Compound Formula 5)
Affinity DataIC50: 1.5nMAssay Description:Successful drug candidate compounds were subjected to numerous biochemical and cellular assays. Purified bacterial β-glucuronidases were challen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 1.56nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622515(US20230312583, Compound I-11)
Affinity DataIC50: 1.58nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622505(US20230312583, Compound I-1)
Affinity DataIC50: 1.59nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476699((R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazi...)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476700(5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethyl...)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476699((R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazi...)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476700(5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethyl...)
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 1.93nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622509(US20230312583, Compound I-5)
Affinity DataIC50: 1.99nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622508(US20230312583, Compound I-4)
Affinity DataIC50: 2.20nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476711(US10870639, Example 26 | ((2R,6R)-4-(3-((5-chloro...)
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476711(US10870639, Example 26 | ((2R,6R)-4-(3-((5-chloro...)
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476708(3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dime...)
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476708(3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dime...)
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476702(N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin...)
Affinity DataIC50: 2.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476702(N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin...)
Affinity DataIC50: 2.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622520(US20230312583, Compound II-1)
Affinity DataIC50: 2.91nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 2.95nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622517(US20230312583, Compound I-13)
Affinity DataIC50: 3.17nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476697(2-((2R,6S)-4-(3-((5-chloro-4-(1H-indole-3-yl)pyrim...)
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476701(chloro-N-(3-cyclopropyl-5-((3,5-dimethyl piperazin...)
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476697(2-((2R,6S)-4-(3-((5-chloro-4-(1H-indole-3-yl)pyrim...)
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476701(chloro-N-(3-cyclopropyl-5-((3,5-dimethyl piperazin...)
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622514(US20230312583, Compound I-10)
Affinity DataIC50: 3.63nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM622507(US20230312583, Compound I-3)
Affinity DataIC50: 3.71nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 4nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: 5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataIC50: 5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM588615(US11542261, Compound I-21 | NCGC00262326)
Affinity DataIC50: 6nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM476712(US10870639, Example 31 | (2R,6S)-4-(3-((5-chloro-4...)
Affinity DataIC50: 6.90nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

Displayed 1 to 50 (of 152 total ) | Next | Last >>
Jump to: